Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CTY
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Abigail P. Johnson | 7.03M | 14.0% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | FMR LLC | 7.03M | 14.0% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | Steven Gillis | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | Kristina Burow | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | Keith Crandell | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | Robert Nelsen | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | ARCH Venture Partners XII, LLC | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | ARCH Venture Partners XII, L.P. | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13D | CTY City Therapeutics, Inc. | ARCH Venture Fund XII, L.P. | 13.69M | 25.6% | SCHEDULE 13D ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Rose Sharon Shabet | 3.73M | 7.0% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Halvorsen Ole Andreas | 3.73M | 7.0% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities Vintage IV (Aggregator) LP | 1.12M | 2.1% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities Vintage IV Portfolio GP LLC | 1.12M | 2.1% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities Vintage IV GP LLC | 1.12M | 2.1% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.61M | 4.9% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities Portfolio GP LLC | 2.61M | 4.9% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities GP LLC | 2.61M | 4.9% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Opportunities Parent GP LLC | 3.73M | 7.0% | SCHEDULE 13G ↗ |
| Oct 26, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Viking Global Investors LP | 3.73M | 7.0% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Raymond Debbane | 4.34M | 8.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Ulys, L.L.C. | 40,094 | 0.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Avicenna Life Sci Master GP LLC | 40,094 | 0.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Avicenna Life Sci Master Fund LP | 40,094 | 0.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Siren, L.L.C. | 4.30M | 8.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Invus Global Management, LLC | 4.30M | 8.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Invus Public Equities Advisors, LLC | 4.30M | 8.1% | SCHEDULE 13G ↗ |
| Oct 22, 2026 | SCHEDULE 13G | CTY City Therapeutics, Inc. | Invus Public Equities, L.P. | 4.30M | 8.1% | SCHEDULE 13G ↗ |
27 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:48 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances